Skip to main content
. 2016 Feb 15;5:e11742. doi: 10.7554/eLife.11742

Figure 3. Pharmacological characterization of the receptor relaying the anorexigenic effects of NDN.

Figure 3.

Mice fasted for 18 hr received a single intraperitoneal injection of flumazenil (a; 10 mg/kg) or PK-11195 (b; 10 mg/kg) diluted in 0.9% NaCl solution, 20 min before icv injection of NDN (10 ng) or vehicle. Mice had access to food 20 min after injection and cumulative food intake was measured during the indicated periods (n=6). (c) Mice fasted for 18 hr were given icv injections of the endozepine metabotropic receptor antagonist cyclo1-8[DLeu5]ODN(11-18) (LV-1075; 100 ng) and NDN (10 ng) (n=6). Mice had access to food 20 min after icv injection and cumulative food intake was measured at the indicated periods. Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test:*p< 0.05; **p<0.01, ***p<0.001.

DOI: http://dx.doi.org/10.7554/eLife.11742.019

Figure 3—source data 1. Impact of flumazenil treatment on the anorexigenic effect of NDN.
DOI: http://dx.doi.org/10.7554/eLife.11742.020
elife-11742-fig3-data1.xlsx (11.1KB, xlsx)
DOI: 10.7554/eLife.11742.020
Figure 3—source data 2. Impact of PK-11195 treatment on the anorexigenic effect of NDN.
DOI: http://dx.doi.org/10.7554/eLife.11742.021
elife-11742-fig3-data2.xlsx (11.2KB, xlsx)
DOI: 10.7554/eLife.11742.021
Figure 3—source data 3. Impact of LV-1075 treatment on the anorexigenic effect of NDN.
DOI: http://dx.doi.org/10.7554/eLife.11742.022
elife-11742-fig3-data3.xlsx (11.1KB, xlsx)
DOI: 10.7554/eLife.11742.022